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Abstract A superantigen designated as Yersinia pseudotuberculosis-derived mitogen (YPM) was purified in an equal manner from both the culture 
supematant and cell lysate of a clinical isolate (KUR-1) of L pseudotuberculosis erotype 4b. A sign&ant proliferative response of human peripheral 
blood mononuclear cells to purified YPM was detectable ven at a concentration of 1 pg/ml. The N-terminal sequence of YPM which included 
23 ammo acid residues was determined, by automated Edman degradation, as Thr-Asp-Tyr-Asp-Asn-Thr-Leu-Asn-Ser-Ile-~o-Ser-~u-~g-Ile-~o- 
Asn-11 e-Ala-Thr-Tyr-Thr-Gly-. This sequence differed from not only all the, hitherto, reported superantigens but also known proteins. While 
molecular weights of known bacterial superantigens are more than 22,000, electrospray ionization mass spectrometry showed that the molecular 
weight of YPM was 14524.4. These results indicate that YPM comprises a novel superantigen with substantial structural differences from other 
bacterial superantigens produced by Gram-positive cocci. 
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1. Intmduction 
Superantigens are highly potent immunostimulatory mole- 
cules that bind, as an intact protein, to outside of the conven- 
tional peptide antigen-binding site of a class II major histocom- 
patibility complex molecule, and are capable of activating 
virtually all T-cells that express particular /? chain variable 
region (V,) of T-cell receptor (TCR) [l-4]. Members of the 
superantigen family include viral superantigens such as the 
minor lymphocyte stimulatory antigens from mouse mammary 
tumour virus and bacterial toxins produced by Staphylococcus 
aureus and other bacteria. The toxins with superantigenic activ- 
ity have been directly implicated in acute and systemic diseases 
in human. The toxicity of bacterial superantigens is thought to 
be mediated by their potent T-cell-stimulating activities, leading 
to lyrnphokine release. 
Yersinia pseudotuberculosis is a Gram-negative enteropatho- 
genie bacillus which induces not only gastrointestinal symp- 
toms but also a variety of systemic symptoms such as fever, 
scarlatiniform rash, mesenteric lymphadenitis, acute renal fail- 
ure, and arthritis [5-71. The clinical pathophysiology of E pseu- 
dotuberculosis infection has many overlapping symptoms 
caused by S. aureus and Streptococcuspyogenes which produce 
a superantigen. Recently, Uchiyama et al. [8,9] and we [lo] have 
independently demonstrated the production of a superantigen 
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by K pseudotuberculosis, and designated the superantigen as 
E pseudotuberculosis-derived mitogen (YPM). While the bio- 
logical property of YPM was superantigenic, YPM was differ- 
ent from the known bacterial superantigens with respect o a 
TCR V, repertoire expressed in selectively activated T-cell pop- 
ulations [8,10]. Furthermore, it has been reported that the T-cell 
response to YPM was not neutralized by antibodies against 
known bacterial superantigens, toxic shock syndrome toxin-l 
(TSST-1) and five types of staphylococcal enterotoxin (SE), 
produced by S. aureus [lo]. These facts implied the possibility 
that YPM is a novel bacterial superantigen with large structural 
differences from the known bacterial superantigens. This 
formed the impetus for the present study in which we report 
the purification, N-terminal sequence, and molecular weight of 
a novel bacterial superantigen produced by Z pseudotubercu- 
lost& 
2. Experimental 
2.1. Bacterial strain and culture conditions 
A clinical strain of I: pseudotuberculosis (KUR-1) belonging to the 
serotype 4b isolated from a patient manifesting Kawasaki disease.-like 
symptom was donated by Dr. N. Takeda (Kurashiki Central Hospital, 
Kurashiki, Japan). The strain was cultured as described previously [lo]. 
2.2. PuriJication of YPh4 from the culture supernatant 
The culture supematant of I! pseudotuberculosis KUR-1 was precip- 
itated with 80% ammonium sulfate. After centrifugation at 15,000 x g 
for 30 min at 4”C, the resulting pellet was resuspended in 10 mM 
sodium phosphate buffer (PH 7.0), and dialyzed against the same 
buffer. Dialyzed samples were subjected to gel filtration on a Sephacryl 
S-200 Superfine column (3 x 100 cm) previously equilibrated with 
10 mM sodium phosphate buffer (PH 7.0), and eluted with the same 
buffer at a flow rate of 33 ml/h. An aliquot of each fraction collected 
in 10 ml was tested for proliferative response of human peripheral blood 
mononuclear cells (PBMC). The mitogenic fractions were concen- 
trated, dialyzed against 20mM Tris-HCI buffer @H 7.8), and then 
purified further by high-performance ion-exchange chromatography 
(HPIEC) and reversed-phase high-performance liquid chromatography 
(RP-HPLC). 
All rights reserved. 
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2.3. Purification of YPM from the cell Iysate 
Cells of Y: pseudotuberculosis KUR-1 collected by centrifugation 
were suspended in 20 mM Tris-HCl buffer (PH 7.2), disrupted by 
sonication, and centrifuged at 10,000 x g for 20 min at 4°C. After 
ultracentrifugation of the supernatant at 100,000 x g for 3 h at 4”C, the 
resulting supernatant was treated with ammonium sulfate (80% satura- 
tion). The precipitates were resuspended, dialyzed against the same 
buffer, and purified further by HPIEC and RP-HPLC. 
2.4. HPIEC 
A sample solution was applied to a TSKgel DEAE-SPW column 
(7.5 x 75 mm) previously equilibrated with 20 mM Tris-HCl buffer (PH 
7.8) and eluted with the equilibration buffer for 5 min, followed by a 
linear gradient of NaCl (O-O.3 M in 25 min) in the same buffer, at a flow 
rate of 1.0 ml/min. 
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Fig. 1. Purification of YPM. (A) HPIEC of the crude YPM obtained 
by Sephacryl S-200 Superfine gel filtration. (B) RP-HPLC of the mito- 
genie peak fraction indicated by an asterisk in (A). An arrow indicates 
the peak fraction exhibiting potent mitogenic activity. (C) Rechromato- 
graphy RP-HPLC of the purified preparation of YPM. 
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Fig. 2. Dose-response curve of human PBMC proliferation stimulated 
by the purified YPM. Values are the mean of three determinants 
f S.E.M. Protein concentration was determined by RP-HPLC using 
ribonuclease A with a molecular weight of 13,682 as the standard. 
2.5. RP-HPLC 
RP-HPLC for the separation of YPM was carried out using a De- 
velosil 3OOC4-HG-5 column (4.6 x 150 mm) previously equilibrated 
with 30% a&on&rile in 0.1% trifluoroacetic acid (TFA) and run with 
a linear gradient of acetonitrile (30-40% in 30 min), at a flow rate of 
1 .o ml/mm. 
2.6. Electrospray ionization mass spectrometry (ESI-MS) 
ES1 mass spectrum was measured by a JEOL JMS-HX/HXllOA 
four-sector tandem mass spectrometer (Tokyo, Japan) equipped with 
an ES1 ion source (Analytica of Branford, Branford, CT). The sample 
was dissolved in an equal volume of mixture of acetonitrile/O.2% TFA 
in water/2-methoxyethanoY2-propanol d delivered at a flow rate of 
1 pl/min. 
2.7. Peptide synthesis 
Chemical synthesis of two peptides NP-I (CTDYDNTLNSIPSLRI) 
and NP-II (CLNSIPSLRIPNIATY) were performed using the continu- 
ous flow solid-phase technique with use of a MilliGen/Biosearch 9050 
peptide synthesizer (Bedford, MA). The peptide chains were elongated 
stepwise on polyethylene glycol polystyrene resin, using optimiid 9- 
fluorenylmethoxycarbonyl chemistry, as previously described [1 l-l 31. 
The synthetic peptides were purified by RP-HPLC and characterized 
by amino acid analysis and fast atom bombardment mass spectrometry, 
giving the expected values. 
2.8. Antisera preparation 
The synthetic peptide with sulfhydryl group (2 mg) in 200 ~1 of a 
conjugation buffer (83 mM sodium phosphate, 150 mM NaCl, 0.1 M 
EDTA, 0.02% NaN3, pH 7.2) was mixed with a solution of the carrier 
protein (bovine serum albumin, 2 mg in 200 ~1 of the conjugation 
buffer), which was previously cationized to an optimum level and acti- 
vated with sulfhydryl reactive maleimide groups [14,15]. The reaction 
mixture was incubated for 2 h at room temperature and then was 
dialyzed against a buffer (83 mM sodium phosphate, 150 mM NaCl, 
pH 7.2). 
Rabbits were immunized with the peptide-carrier protein conjugate 
(0.1 mg) emulsified with Freund complete adjuvant by injecting into 
each of ten subcutaneous sites on the back. After 3 weeks, the rabbits 
were boosted with the conjugates in Freund complete/incomplete ad- 
juvant. Antisera were obtained by bleeding the rabbits one week after 
the booster and were tested for antibody response by enzyme-linked 
immunosorbent assay. 
Rabbit antiserum against YPM was raised by repeated immuniza- 
tions (3 times at 4-week intervals) with ca. 25 pg of the purilied prepa- 
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ration. Antiserum obtained 10 days after the last booster was tested for 
mitogenic activity-neutralizing response. 
2.9. Assay for proltjerative response 
Proliferative response was measured with human PBMC cultures as 
described previously [lo]. For neutralization experiments, PBMC cul- 
tures were incubated with the purified YPM (ca. 10 pg/ml) in the 
presence or absence of each antiserum (10 ,ul). 
3. Results 
3.1. PuriJication of YPMfrom the culture supernatant 
Crude YPM obtained from the culture supematant of 
L pseudotuberculosis 4b strain KUR-1 was partially puritled 
by ammonium sulfate precipitation and gel filtration, as de- 
scribed in section 2. The mitogenic fractions on human PBMC 
were purified further by HPIEC. One major peak and several 
minor peaks were observed in the elution prolile (Fig. IA), and 
mitogenic activity was eluted only in the major peak fraction. 
This fraction was subjected to RP-HPLC to give a pure mitogen 
and the fraction which showed potent mitogenic activity was 
eluted as one of the quite minor peaks to yield pure YPM (Fig. 
1B). Proliferative response of human PBMC to purified YPM 
was detectable ven at a concentration of 1 pg/ml (Fig. 2). The 
fraction with marked mitogenicity was subjected to rechroma- 
tography to give a sharp and single peak, indicating purification 
to high homegeneity (Fig. 1C). Furthermore, rabbit antiserum 
against the purified preparation completely neutralized the 
YPM-induced proliferation (Fig. 3). This also showed that the 
YPM preparation obtained here was highly homogeneous. 
3.2. The N-terminal amino acid sequence and molecular weight 
of YPM 
Automated Edman degradation of purified YPM, using a 
Shimadzu PSQ-1 gas-phase protein sequencer (Kyoto, Japan), 
provided the N-terminal sequence of 23 amino acid residues as 
Thr-Asp-Tyr-Asp-Asn-Thr-Leu-Asn-Ser-Ile-Pro-Ser-~u-Arg- 
Ile-Pro-Am-11 e-Ala-Thr-Tyr-Thr-Gly-. For confirmation that 
the determined N-terminal sequence is certainly that of YPM, 
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Fig. 3. Inhibition of the YPM-induced proliferation by antisera against 
puri6ed YPM and against the synthetic peptides NP-I and NP-II. 
Values are the mean of three determinants + S.E.M. The number in a 
cohmm denotes the percentage of inhibition, which was calculated as 
the ratio of the difference between the observed and blank cpm values 
to that between maximum (obtained in the incubation with only YPM) 
and blank cpm values. 
rabbit antisera against synthetic peptides NP-I and NP-II were 
raised and their neutralizing capabilities were tested. Peptides 
NP-I and NP-II represent partial sequences Thr’-IlerS and 
Leu7-Ty?’ of the determined sequence, respectively, and pos- 
sess a cysteine residue at the N-terminus for conjugation with 
the maleimide-activated carrier protein. As shown in Fig. 3, the 
proliferative response of human PBMC to YPM was partially 
inhibited by antisera against NP-I and NP-II. 
In the ES1 mass spectrum of purified YPM, four intense 
signals were observed (Fig. 4). From the observed values of 
these signals, the molecular weight of the YPM was calculated 
to be 14,524.4 f 0.3. 
3.3. Purljication of YPMfrom cell lysate 
Since considerable mitogenic activity was detected in the cell 
lysate, we purified the mitogen from the cell lysate to compare 
with YPM obtained from the culture supematants. The cell 
lysate of Y: pseudotuberculosis strain KUR-1, obtained as de- 
scribed in section 2, was purified by ammonium sulfate precip- 
itation, HPIEC and by RP-HPLC using the same conditions as 
in the purification from the culture supematant. At each step, 
potent mitogenic activity was eluted in a peak fraction with 
nearly identical retention time to that of the active peak fraction 
shown in Fig. 1 (data not shown). The N-terminal 15 amino 
acid residues of the purified mitogen were determined to be 
identical to that from the culture supematant. ESI-MS of the 
purified preparation from the cell lysate showed that the molec- 
ular weight was 14,524.2 f 0.1. These results indicate that YPM 
preparation from both the supematant and the cell lysate are 
the same molecules. 
4. DiWlssion 
In the present study, a superantigen designated YPM was 
purified to homogeneity from both the culture supematant and 
cell lysate of a clinical isolate of Z pseudotuberculosis, and its 
N-terminal amino acid sequence and molecular weight were 
determined. Although Gram-positive coccal superantigens, 
such as TSST- 1, SEs and streptococcal pyrogenic exotoxins, are 
well characterized, the present study concerned the purification 
and characterization of a bacterial superantigen produced by 
a Gram-negative bacillus. 
While the amino acid sequences of various super-antigens 
produced by Gram-positive cocci are known [16-281, neither 
the N-terminal sequence nor the sequence of other regions of 
these superantigens were identical to the N-terminal sequence 
of the purified YPM determined in this study. Furthermore, the 
sequence with 23 amino acid residues was not notably homolo- 
gous to any sequence of previously characterized proteins. Al- 
though molecular sizes of the previously documented bacterial 
superantigens range from 22,000 to 29,000, ESI-MS of the 
purified YPM showed its molecular weight to be 14,524.4. 
From these results based on the protein chemistry, it is con- 
cluded that YPM is a novel superantigen whose molecular 
structure is quite different from Gram-positive coccal superan- 
tigens. 
The present study showed that the mitogenic substances 
present in both the culture supematant and the cell lysate are 
identical. This implied that YPM is synthesized in the cell as 
the active form and is secreted as such extracellularly without 
any further processing. 
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Fig. 4. ES1 mass spectrum of the puril%d YPM. From each observed 
m/z value of four multiply charged ion signals ([M + nw), molecular 
weight of purified YPM was calculated to be 14524.4 f 0.3. 
Braun et al. 1291 have cautioned that the mitogenicity on 
T-cells could be due to similar minute contaminations with 
potent superantigens that are undetectable by current biochem- 
ical methods but are, nonetheless, extremely effective in stimu- 
lating sensitive T-cells. Consequently, an argument can be 
raised that the N-terminal sequence and molecular weight de- 
termined in this study are certainly the character of YPM. We 
confirmed this by demonstrating that synthetic peptides har- 
boring the N-terminal sequence determined here could induced 
a neutralizing antibody for the human PBMC proliferation 
stimulated by YPM. 
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